1. Home
  2. NMFC vs VIR Comparison

NMFC vs VIR Comparison

Compare NMFC & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Mountain Finance Corporation

NMFC

New Mountain Finance Corporation

N/A

Current Price

$8.16

Market Cap

972.8M

Sector

Finance

ML Signal

N/A

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

N/A

Current Price

$9.45

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NMFC
VIR
Founded
2010
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
972.8M
1.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NMFC
VIR
Price
$8.16
$9.45
Analyst Decision
Hold
Strong Buy
Analyst Count
4
8
Target Price
$10.00
$29.13
AVG Volume (30 Days)
1.3M
1.5M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
15.80%
N/A
EPS Growth
N/A
17.49
EPS
N/A
N/A
Revenue
N/A
$68,556,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$131.58
P/E Ratio
$12.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.91
$4.16
52 Week High
$11.98
$9.84

Technical Indicators

Market Signals
Indicator
NMFC
VIR
Relative Strength Index (RSI) 38.84 76.06
Support Level $7.91 $4.54
Resistance Level $8.68 N/A
Average True Range (ATR) 0.25 0.50
MACD 0.01 0.12
Stochastic Oscillator 33.77 98.46

Price Performance

Historical Comparison
NMFC
VIR

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Share on Social Networks: